ArticleSurgery today2026
Surgical management for symptomatic primary tumors in unresectable stage IV rectal cancers.
Article in Surgery today, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThis study aimed to describe the clinical characteristics, surgical selection patterns, and postoperative outcomes of patients who underwent either primary tumor resection (PTR) or ostomy for symptomatic unresectable stage IV rectal cancer in a real-world clinical setting.
methodsWe retrospectively reviewed 63 patients who underwent palliative surgery at Aichi Cancer Center Hospital between 2005 and 2023: PTR (n = 39) or ostomy (n = 24). The outcomes included postoperative complications, time to chemotherapy, and overall survival.
resultsLiver metastases were observed in 89.7% of the PTR group and 50.0% of the ostomy groups (p < 0.001), whereas distant lymph node metastases were more frequent in the ostomy group (p = 0.007). Postoperative complications were observed in 15.4% of the PTR group and 8.3% of the ostomy groups. The median interval to chemotherapy was 41 days in the PTR group and 15 days in the ostomy group (p < 0.001). Four patients (16.7%) in the ostomy group experienced tumor-related issues during chemotherapy. The five-year overall survival was 10.3% in the PTR group and 4.1% in the ostomy group (p = 0.390).
conclusionsPTR may delay chemotherapy owing to postoperative complications. These findings suggest the need for careful consideration of the risks and benefits when selecting surgical options for symptom control in patients with unresectable stage IV rectal cancer.
Indexed as
Identifiers
41591530What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.